Literature DB >> 16196383

Targeted gene expression analysis in hemimegalencephaly: activation of beta-catenin signaling.

Jia Yu1, Marianna Baybis, Allana Lee, Guy McKhann, Diane Chugani, William J Kupsky, Eleonora Aronica, Peter B Crino.   

Abstract

Hemimegalencephaly (HMEG) is a developmental brain malformation characterized by unilateral hemispheric enlargement, cytoarchitectural abnormalities, and an association with epilepsy. To define the developmental pathogenesis of HMEG, the expression of 200 cell signaling, growth, angiogenic, and transcription factor genes was assayed in HMEG samples (n=8) with targeted cDNA arrays. Differential expression of 31 mRNAs across the 4 gene families was identified in HMEG compared with control cortex. Increases in growth and transcription factor genes included JNK-1, cyclic AMP response element binding protein (CREB), and tuberin mRNAs and decreases included insulin-like growth factor-1 (IGF-1), transforming growth factor beta-3 (TGF-beta3), and NFkB mRNAs. Increased expression of cyclin D1, c-myc, and WISP-1 mRNAs in HMEG suggested activation of the Wnt-1/beta-catenin cascade. Western analysis demonstrated increased levels of non-phosphorylated beta-catenin, which transcriptionally activates cyclin D7 and c-myc genes, but reduced levels of Ser33/Ser37/Thr41 phospho-beta-catenin, which is essential for beta-catenin-inactivation, in HMEG. Altered expression of 31 mRNAs from 4 gene families in human HMEG may lead to aberrant cell growth and hemispheric enlargement during brain development. Enhanced cyclin D1 and c-myc transcription likely reflects increased transcriptionally active beta-catenin due to decreased Ser33/Ser37/Thr41 phospho-beta-catenin and suggests activation of the Wnt-1/beta-catenin cascade in HMEG.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16196383     DOI: 10.1111/j.1750-3639.2005.tb00518.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  6 in total

1.  De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly.

Authors:  Jeong Ho Lee; My Huynh; Jennifer L Silhavy; Sangwoo Kim; Tracy Dixon-Salazar; Andrew Heiberg; Eric Scott; Vineet Bafna; Kiley J Hill; Adrienne Collazo; Vincent Funari; Carsten Russ; Stacey B Gabriel; Gary W Mathern; Joseph G Gleeson
Journal:  Nat Genet       Date:  2012-06-24       Impact factor: 38.330

Review 2.  Epilepsy related to developmental tumors and malformations of cortical development.

Authors:  Eleonora Aronica; Peter B Crino
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

3.  Clinical and imaging characteristics of localized megalencephaly: a retrospective comparison of diffuse hemimegalencephaly and multilobar cortical dysplasia.

Authors:  Masumi Nakahashi; Noriko Sato; Akira Yagishita; Miho Ota; Yoshiaki Saito; Kenji Sugai; Masayuki Sasaki; Jun Natsume; Yoshito Tsushima; Makoto Amanuma; Keigo Endo
Journal:  Neuroradiology       Date:  2009-08-12       Impact factor: 2.804

4.  DNASE1L3 inhibits proliferation, invasion and metastasis of hepatocellular carcinoma by interacting with β-catenin to promote its ubiquitin degradation pathway.

Authors:  Bo Li; Yu-Zhen Ge; Wei-Wei Yan; Bin Gong; Kun Cao; Rui Zhao; Chao Li; Ye-Wei Zhang; Yi-Heng Jiang; Shi Zuo
Journal:  Cell Prolif       Date:  2022-06-24       Impact factor: 8.755

5.  STRADA-mutant human cortical organoids model megalencephaly and exhibit delayed neuronal differentiation.

Authors:  Louis T Dang; Shivanshi Vaid; Grace Lin; Preethi Swaminathan; Jordan Safran; Anna Loughman; Monica Lee; Trevor Glenn; Fernanda Majolo; Peter B Crino; Jack M Parent
Journal:  Dev Neurobiol       Date:  2021-04-27       Impact factor: 3.102

6.  Downregulation of ribosome biogenesis during early forebrain development.

Authors:  Kevin F Chau; Morgan L Shannon; Ryann M Fame; Erin Fonseca; Hillary Mullan; Matthew B Johnson; Anoop K Sendamarai; Mark W Springel; Benoit Laurent; Maria K Lehtinen
Journal:  Elife       Date:  2018-05-10       Impact factor: 8.140

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.